Incannex Boasts $75M Cash, No Debt and Negative EV as Phase 2 Dosing Approaches
Incannex holds approximately $75 million in cash with zero debt, resulting in a negative enterprise value against its $46 million market capitalization. Proceeds will fund the DReAMzz Phase 2 crossover dose-optimization study for IHL-42X in obstructive sleep apnea while preserving capital for an optimized Phase 3 program and PSX-001 advancement.
1. Strong Financial Position
Incannex’s balance sheet now reflects about $75 million in cash with no debt, while its $46 million market capitalization produces a negative enterprise value. Management views the participation of healthcare-focused institutional investors in the recent financing as validation of its clinical pipeline and long-term value potential.
2. DReAMzz Phase 2 Dose-Optimization Study
Proceeds from the financing will fund the DReAMzz Phase 2 crossover dose-optimization study of IHL-42X for obstructive sleep apnea, designed to refine the ratio of dronabinol and acetazolamide to maximize both physiological endpoints and patient-reported outcomes. Dosing is expected to begin in the coming months, with preserved capital allocated for an optimized Phase 3 program.
3. PSX-001 Development for GAD
Incannex continues to advance PSX-001, its oral synthetic psilocybin therapy for generalized anxiety disorder, after positive clinical outcomes. The program benefits from an open IND, guidance from a psychiatry and psychedelic therapies advisory board, and a clear pathway to upcoming regulatory and clinical milestones.